Cell type‐specific molecular mechanisms and implications of necroptosis in inflammatory respiratory diseases
Immunological Reviews · 2024
DOI: 10.1111/imr.13282 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Immunological Reviews, 2024. Verfasst von Ying Guo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology, Head and Neck Surgery, Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, China. Hauptthemen laut MEDLINE: Protein Kinases, Respiratory Tract Diseases. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 190 Literaturangaben. Gefördert von: China Postdoctoral Science Foundation, the Key Research and Development Program of Shandong Province (Major Science and Technology Innovation Project), the National Natural Science Foundation of China.
Abstract (Originalsprache)
Necroptosis is generally considered as an inflammatory cell death form. The core regulators of necroptotic signaling are receptor‐interacting serine–threonine protein kinases 1 (RIPK1) and RIPK3, and the executioner, mixed lineage kinase domain‐like pseudokinase (MLKL). Evidence demonstrates that necroptosis contributes profoundly to inflammatory respiratory diseases that are common public health problem. Necroptosis occurs in nearly all pulmonary cell types in the settings of inflammatory respiratory diseases. The influence of necroptosis on cells varies depending upon the type of cells, tissues, organs, etc., which is an important factor to consider. Thus, in this review, we briefly summarize the current state of knowledge regarding the biology of necroptosis, and focus on the key molecular mechanisms that define the necroptosis status of specific cell types in inflammatory respiratory diseases. We also discuss the clinical potential of small molecular inhibitors of necroptosis in treating inflammatory respiratory diseases, and describe the pathological processes that engage cross talk between necroptosis and other cell death pathways in the context of respiratory inflammation. The rapid advancement of single‐cell technologies will help understand the key mechanisms underlying cell type‐specific necroptosis that are critical to effectively treat pathogenic lung infections and inflammatory respiratory diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otorhinolaryngology, Head and Neck Surgery, Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, China.
- Shandong Provincial Clinical Research Center for Otorhinolaryngologic Diseases, Yantai, Shandong, China.
- Key Laboratory of Spatiotemporal Single-Cell Technologies and Translational Medicine, Yantai, Shandong, China.
- Department of Endocrinology, Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, China.
- Department of General Surgery, The First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei, China.
- Tumor Research Institute, The First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei, China.
ORCID-Profile: Xueliang Wu
Förderung
- China Postdoctoral Science Foundation
- the Key Research and Development Program of Shandong Province (Major Science and Technology Innovation Project)
- the National Natural Science Foundation of China
- the Natural Science Foundation of Shandong Province, China
Zitieren
APA
Guo, Y., Zhou, J., Wang, Y., Wu, X., Mou, Y., & Song, X. (2024). Cell type‐specific molecular mechanisms and implications of necroptosis in inflammatory respiratory diseases. Immunological Reviews. https://doi.org/10.1111/imr.13282
Vancouver
Guo Y, Zhou J, Wang Y, Wu X, Mou Y, Song X. Cell type‐specific molecular mechanisms and implications of necroptosis in inflammatory respiratory diseases. Immunological Reviews. 2024. doi:10.1111/imr.13282
BibTeX
@article{Guo2024,
author = {Guo, Ying and Zhou, Jin and Wang, Yaqi and Wu, Xueliang and Mou, Yakui and Song, Xicheng},
title = {Cell type‐specific molecular mechanisms and implications of necroptosis in inflammatory respiratory diseases},
journal = {Immunological Reviews},
year = {2024},
doi = {10.1111/imr.13282}
}
EUVIMED